A method of obtaining vitamin D from shiitake includes a) adding ethanol to shiitake powder, followed by reflux extraction, to prepare a shiitake extract; and (b) irradiating ultraviolet (UV) light to the shiitake extract prepared in step (a). When shiitake extracts are obtained and exposed to ultraviolet light under specific conditions, the content of vitamin D2 in the shiitake extracts may be increased.

This invention discloses nano-dimensional compositions of psychedelic drugs, entheogens, and medicinal mushrooms formed from lipids, polymers, stabilizers, mucoadhesives, permeation enhancers, and chemical stabilizers for delivering stable dosage forms by intraoral, gastrointestinal, transdermal, and intranasal, routes of administration. Disclosed are unified product extraction and manufacturing of stable nano-dimensional dosage forms of psychedelic drugs, entheogen, and medicinal mushrooms, and methods for improving their pharmacokinetics, pharmacodynamics, and efficacy. Also disclosed are methods for dephosphorylating the precursor psilocybin into active psilocin molecules, and fast-acting, nano-dimensional structures of psychedelic drugs taken by intranasal and intraoral routes of administration producing activity onset in less than 10 minutes.

This invention discloses nano-dimensional compositions of psychedelic drugs, entheogens, and medicinal mushrooms formed from lipids, polymers, stabilizers, mucoadhesives, permeation enhancers, and chemical stabilizers for delivering stable dosage forms by intraoral, gastrointestinal, transdermal, and intranasal, routes of administration. Disclosed are unified product extraction and manufacturing of stable nano-dimensional dosage forms of psychedelic drugs, entheogen, and medicinal mushrooms, and methods for improving their pharmacokinetics, pharmacodynamics, and efficacy. Also disclosed are methods for dephosphorylating the precursor psilocybin into active psilocin molecules, and fast-acting, nano-dimensional structures of psychedelic drugs taken by intranasal and intraoral routes of administration producing activity onset in less than 10 minutes.

The present invention provides a pharmaceutical composition for adjunctively treating cancer. Differing from conventional therapies commonly using anti-cancer drugs and/or radiation substances to cause the apoptosis of cancer cells, the present invention particularly adopts an ethanol extract of Taiwanofungus camphorata (TCEE), an ethanol extract of Ganoderma lucidum (GLEE) or a combination of the TCEE and the GLEE as the a novel pharmaceutical composition for causing the apoptosis of lung cancer cells A594, hepatoma cells Huh 7, breast cancer cells MDA-MB 231, and colorectal cancer cells HT 29. Moreover, differing from conventionally-used anti-cancer drugs and radiation substances always causing some side-effects such as nausea, vomit, and poor appetite, this novel pharmaceutical composition can not only be used for adjunctively treating cancer, but also possesses many healthy effects, including: detoxification, enhancing immunity, and increasing appetite.

The present invention provides a pharmaceutical composition for adjunctively treating cancer. Differing from conventional therapies commonly using anti-cancer drugs and/or radiation substances to cause the apoptosis of cancer cells, the present invention particularly adopts an ethanol extract of Taiwanofungus camphorata (TCEE), an ethanol extract of Ganoderma lucidum (GLEE) or a combination of the TCEE and the GLEE as the a novel pharmaceutical composition for causing the apoptosis of lung cancer cells A594, hepatoma cells Huh 7, breast cancer cells MDA-MB 231, and colorectal cancer cells HT 29. Moreover, differing from conventionally-used anti-cancer drugs and radiation substances always causing some side-effects such as nausea, vomit, and poor appetite, this novel pharmaceutical composition can not only be used for adjunctively treating cancer, but also possesses many healthy effects, including: detoxification, enhancing immunity, and increasing appetite.

The present invention relates to the use of a brown Flammulina velutipes extract for inhibiting acute kidney injury caused by cisplatin. With the water extract of brown Flammulina velutipes, which reduces the renal histological changes, the production of creatinine, blood urea nitrogen in the acute kidney injury caused by cisplatin.

The present invention relates to the use of a brown Flammulina velutipes extract for inhibiting acute kidney injury caused by cisplatin. With the water extract of brown Flammulina velutipes, which reduces the renal histological changes, the production of creatinine, blood urea nitrogen in the acute kidney injury caused by cisplatin.

The present invention is a method of wowing mushrooms, preferably but not necessarily) Basiomycetes mushrooms, on a substrate that includes unrefined, live or dried cannabis plants (whole or particulated) preferably those cannabis, strains high in CBD and low in THC or containing a preferred ratio thereof, as part or all of the growth medium for the mushrooms.

The present invention is a method of wowing mushrooms, preferably but not necessarily) Basiomycetes mushrooms, on a substrate that includes unrefined, live or dried cannabis plants (whole or particulated) preferably those cannabis, strains high in CBD and low in THC or containing a preferred ratio thereof, as part or all of the growth medium for the mushrooms.

The present invention is a method of wowing mushrooms, preferably but not necessarily) Basiomycetes mushrooms, on a substrate that includes unrefined, live or dried cannabis plants (whole or particulated) preferably those cannabis, strains high in CBD and low in THC or containing a preferred ratio thereof, as part or all of the growth medium for the mushrooms.